Issue link: https://nebusinessmedia.uberflip.com/i/1065590
HEALTH CARE DECEMBER 24, 2018 • HARTFORD BUSINESS JOURNAL | 63 LARGEST BIOSCIENCE/BIOTECHNOLOGY COMPANIES IN CONNECTICUT (Ranked by number of employees as of October 2018) Source: BioCT, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and IDEXX Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees statewide. Branford's mAbChem Lab closed in 2018; research is being continued by New England Discovery Partners. Melinta Therapeutics' New Haven office is closed as of Nov. 30, 2018. Bristol-Myers Squibb Co.'s Wallingford site is on schedule to be completely closed by year-end 2018. (a) An additional 2,700 contractors. (b) Succeeded Paul R. Fonteyne, effective March 1, 2018. (c) Data from 2017 survey. (d) With an additional R&D operation in Branford. (e) Moved headquarters to Boston, Mass. in 2018; Center of Excellence still located in New Haven. (f) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (g) Paris-based Sanofi acquired Protein Sciences Corp., effective Aug. 28, 2017. (h) Founding year for Protein Sciences Corp. (i) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher. Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of October 2018) Rank Company Headquarters No. of employees in CT Focus Year founded Top executive 1 Pfizer Inc. 558 Eastern Point Road Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 (a) Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trials, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO John Burkhardt Senior vice president, Drug Safety R&D 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; boehringer- ingelheim.us Ridgefield, CT 2,500 Development and manufacture of human and animal healthcare products 1885 Wolfgang Baiker (b) President & CEO 3 PerkinElmer Inc. (c) 710 Bridgeport Ave. Shelton, CT 06484 (d) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Detection, imaging, informatics and services innovating for a healthier world 1937 Robert F. Friel Chairman & CEO 4 Alexion Pharmaceuticals Inc. (e) 100 College St. New Haven, CT 06510 475-230-2596; alexion.com Boston, MA 450 Severe and life-threatening rare disorders 1992 Ludwig N. Hantson CEO 5 The Jackson Laboratory for Genomic Medicine (c) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 257 Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (f) Charles Lee Scientific director 6 Innovative Medical Products Inc. 87 Spring Lane Plainville, CT 06062 860-793-0391; www.impmedical.com Plainville, CT 150 Design and manufacture of patient positioning devices for orthopedic surgical procedures 1983 Alan Wasley CEO 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 103 Inhalation product technologies 1991 Michael Castagna CEO 8 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 78 Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 John Houston President & CEO 9 Sanofi Pasteur (g) 1000 Research Parkway Meriden, CT 06450 203-427-2403; sanofi.com Swiftwater, PA 71 Vaccine development and protein production 1983 (h) Olivier Brandicort CEO 10 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, Clinton CT 63 Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 11 Biohaven Pharmaceutical Holding Co. LTD 215 Church St. New Haven, CT 06510 203-404-0410; biohavenpharma.com New Haven, CT 54 Neuroscience 2013 Vlad Coric CEO 12 CARA Therapeutics 107 Elm St., 9th Floor, 4 Stamford Plaza Stamford, CT 06902 203-406-3700; www.caratherapeutics.com Stamford, CT 47 Development of therapeutics to treat human diseases associated with pruritus, pain and inflammation 2004 Derek Chalmers Director, president & CEO 13 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 45 Factor D immune system inhibitors 2000 Joe Truitt President & CEO 14 Celldex Therapeutics Inc. (i) 688 East Main St., Suite 1A Branford, CT 06405 203-483-3500; celldex.com Hampton, NJ 25 Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators 2005 Anthony Marucci President & CEO 15 CaroGen Corp. 400 Farmington Ave. Farmington, CT 06032 203-815-5782; carogencorp.com Farmington, CT 12 Development of immunotherapy vaccines for infectious disease, cancer and the treatment of patients with chronic hepatitis B virus 2012 Bijan Almassian President & CEO 16 Azitra Inc. 400 Farmington Ave., CB126 RM1836 Farmington, CT 06032 203-599-0700; azitrainc.com Farmington, CT 10 Bacterial-based therapeutics for skin conditions 2014 Richard Andrews CEO 16 Synovel Laboratory LLC 375 Morgan Lane, Unit 204B West Haven, CT 06516 203-545-9462; synovellab.com West Haven, CT 10 Medicinal and process chemistry support for biotech and pharmaceuticals companies, university and nonprofit organizations 2014 Ho-Yin Lo Founder & CEO 18 BioPharmaWorks LLC 93 Shennecossett Road Groton, CT 06340 860-912-6101; biopharmaworks.com Groton, CT 9 Drug discovery, medicinal chemistry, structural biology, pharmacokinetics, ADME and process chemistry 2015 Bob Volkmann Chief science officer 19 Artificial Cell Technologies 5 Science Park, Suite 13 New Haven, CT 06511 203-772-3430; artificialcelltech.com New Haven, CT 8 Vaccine development 2006 Donald S. Masters President & CEO Source: BioCT, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and IDEXX Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees statewide. Branford's mAbChem Lab closed in 2018; research is being continued by New England Discovery Partners. Melinta Therapeutics' New Haven office is closed as of Nov. 30, 2018. Bristol-Myers Squibb Co. Wallingford site is on schedule to be completely closed by year-end 2018. (a) An additional 2,700 contractors. (b) Succeeded Paul R. Fonteyne, effective March 1, 2018. (c) Data from 2017 survey. (d) With an additional R&D operation in Branford. (e) Moved headquarters to Boston, Mass. in 2018; Center of Excellence still located in New Haven. (f) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (g) Paris-based Sanofi acquired Protein Sciences Corp., effective Aug. 28, 2017. (h) Founding year for Protein Sciences Corp. (i) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher. Pfizer announced in Jan. 2018 that it would stop its neuroscience early development programs mostly concentrated on Alzheimer's and Parkinson's diseases, leading to about 100 job cuts in Groton. Connecticut Innovations agreed to write off Jackson Laboratory's $165.9 million state loan balance, which the nonprofit medical research institution used to build, fit-out and equip its Farmington campus. Arvinas, which is creating a new class of cancer drugs based on protein degradation, said it raised $55 million in April to fund development of its cancer treatment.